{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:21:44Z","timestamp":1784366504380,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clml.2020.02.005","type":"journal-article","created":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T02:24:29Z","timestamp":1581733469000},"page":"341-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["AML: New Drugs but New Challenges"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1734-5817","authenticated-orcid":false,"given":"Alan","family":"Burnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.02.005_bib1","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1200\/JCO.2013.52.3480","article-title":"Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia","volume":"32","author":"Pastore","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study","volume":"28","author":"Becker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib5","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.02.005_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.02.005_bib7","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib8","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib12","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib13","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity: a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A\u00a0randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib15","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.02.005_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.02.005_bib17","first-page":"467","article-title":"Prognostic impact of NPM1\/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia treated with international RATIFY study","volume":"130","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"German-Austrian AML Study Group. Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3ITD","volume":"133","author":"Schlenck","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2018-99-112614","article-title":"Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre Sormain trial","volume":"132","author":"Burchert","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jnci\/djm328","article-title":"Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia","volume":"100","author":"Zhang","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2020.02.005_bib21","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2020.02.005_bib22","first-page":"CT184","article-title":"Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed\/refractory acute myeloid leukemia: results from the phase III ADMIRAL trial","volume":"79","author":"Perl","year":"2019","journal-title":"AACR Annual Meeting"},{"key":"10.1016\/j.clml.2020.02.005_bib23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3 ITD acute myeloid leukemia (QuANTUM-R), a multicentre, randomszed, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.02.005_bib25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib26","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib27","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib28","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V128.22.906.906","article-title":"Survival following allogeneic hematopoietic cell transplantation in older high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection versus standard cytarabine and daunorubicin: subgroup analysis of a large phase III trial","volume":"128","author":"Lancet","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib29","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","article-title":"Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg","volume":"16","author":"Larson","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.02.005_bib31","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib32","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A\u00a0phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib34","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozagamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib36","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.02.005_bib37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib38","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group Trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","article-title":"Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications","volume":"29","author":"Marcucci","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib40","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2013-03-493197","article-title":"Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia","volume":"121","author":"DiNardo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib41","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib42","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.02.005_bib43","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.005_bib45","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2014.55.1564","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older adults","volume":"32","author":"Klepin","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib46","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.3324\/haematol.2018.191361","article-title":"Phase 3 results for vosaroxin\/cytarabine in the subset of patients\u00a0\u226560 years old with refractory\/early relapsed acute myeloid leukemia","volume":"103","author":"Ravandi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.02.005_bib47","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabne alone in older patients with relapsed or refractory acute myelogenous leukaemia: results from the CLASSIC I trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib48","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A\u00a0comparison of low-dose cyatarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.02.005_bib49","first-page":"1758","article-title":"The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics","volume":"5","author":"Kornblau","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.02.005_bib50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.02.005_bib51","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2020.02.005_bib52","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A\u00a0novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2020.02.005_bib53","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.02.005_bib55","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/cas.13019","article-title":"Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells","volume":"107","author":"Fukushima","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2020.02.005_bib56","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1038\/onc.2010.375","article-title":"Hedgehog signaling maintains chemoresistance in myeloid leukemic cells","volume":"29","author":"Queiroz","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2020.02.005_bib57","first-page":"e339","article-title":"Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase I safety and pharmacokinetics study","volume":"2","author":"Martinelli","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.02.005_bib58","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1078-0432.CCR-17-2824","article-title":"Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS","volume":"24","author":"Savona","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.02.005_bib59","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/ajh.25238","article-title":"Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results","volume":"93","author":"Cortes","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.02.005_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukmeia or high risk myelodysplastic syndrome","volume":"33","author":"Cort\u00e9s","year":"2019","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:03Z","timestamp":1761870903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2152265020300859"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.02.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AML: New Drugs but New Challenges","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}